As a licensee of Exentis Group AG, New York-based Laxxon Medical has entered into a long-term strategic cooperation with the international drug manufacturer Hovione. As part of the agreement, Hovione will manufacture 3D-printed tablets at its manufacturing facilities in Portugal using the industrial 3D technology platform developed by Exentis, further details of which can be found in a press release. Manufacturing activities are set to follow at locations in the US state of New Jersey in due course. Compared to conventionally manufactured tablets, these tablets have a freely adjustable drug release profile in the human body.
Exentis, located in Stetten in the canton of Aargau, Switzerland, offers a 3D technology platform for industrialized additive manufacturing. It enables the production of millions of industrial components or clean room applications such as tablets on a single 3D production system. Materials including metals, ceramics, polymers, pharmaceutical and bioprinting products can be processed. Exentis customers have the option of choosing between in-house manufacturing under license agreements and having their applications produced by Exentis as a contract manufacturer.
Hovione is a global supplier of drug substances, intermediate products and drugs. The company has four sites in the USA, Portugal, Ireland and China that have been inspected by the US Food and Drug Administration (FDA), as well as development labs in the USA and Portugal.
“The strategic cooperation will further accelerate the broad deployment of our clean room 3D technology and production systems within the pharmaceutical industry”, comments Gereon Heinemann, CEO of the Exentis Group AG, in the press release.
